RecruitingPhase 2NCT07506109
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Studying Cerebellar malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Intervention
- Ipilimumab N01(drug)
- Enrollment
- 49 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (4)
- Peking union medical college hospital, Beijing, Beijing Municipality, China
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- West China Hospital Sichuan University, Chengdu, Sichuan, China
- Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07506109 on ClinicalTrials.govOther trials for Cerebellar malformation
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508631Friedreich Ataxia Nerve UltrasundCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT07500103Spatiotemporal Entrainment Neuromodulation Targeting Cerebello-Cerebral Circuits to Enhance Cognitive and Social Rehabilitation in Cerebellar DiseasesI.R.C.C.S. Fondazione Santa Lucia